Anxiolytic-like effects through a GLUK5 kainate receptor mechanism

Neuropharmacology

Volumn 52, Issue 7, 2007, Pages 1482-1487

  Alt, Andrew ^a   Weiss, Brianne ^a   Ornstein, Paul L ^a   Gleason, Scott D ^a   Bleakman, David ^a   Stratford Jr , Robert E ^a   Witkin, Jeffrey M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

AMPA receptors; Anxiolytic drugs; Chlordiazepoxide; GYKI53655; Kainate receptors; LY382884; Rats

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 (4 CARBOXYBENZYL) 1,2,3,4,4A,5,6,7,8,8A DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; BENZODIAZEPINE; CHLORDIAZEPOXIDE; KAINIC ACID RECEPTOR; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; GLUR5 KAINATE RECEPTOR; ISOQUINOLINE DERIVATIVE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LITERATURE; MALE; MODULATION; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; VALIDATION STUDY; ANIMAL; ANIMAL BEHAVIOR; BINDING COMPETITION; BRAIN; CELL LINE; DOSE RESPONSE; DRUG EFFECT; INSTRUMENTAL CONDITIONING; METABOLISM; PHYSIOLOGY; PLASMA; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BINDING, COMPETITIVE; BRAIN; CELL LINE, TRANSFORMED; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOQUINOLINES; MALE; PLASMA; PROTEIN SUBUNITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, KAINIC ACID;

EID: 34247571364     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.02.005     Document Type: Article

References (29)

1. Agmo A., Galvan A., Heredia A., and Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology (Berl.) 120 2 (1995 Jul) 186-194
2. Alt A., Weiss B., Ogden A.M., Knauss J.L., Oler J., Ho K., Large T.H., and Bleakman D. Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46 (2004) 793-806
3. Alt A., Weiss B., Ogden A.M., Li X., Gleason S.D., Calligaro D.O., Bleakman D., and Witkin J.M. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology (Berl.) (2006 Feb 10) 1-8
4. Benvenga M.J., Ornstein P.L., and Leander J.D. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons. J. Pharmacol. Exp. Ther. 175 (1995) 164-170
5. Bleakman D., Ogden A.M., Ornstein P.L., and Hoo K. Pharmacological Characterization of a GluR6 receptor in cultured hippocampal neurons. Eur. J. Pharmacol. 378 (1999) 331-337
6. Bortolotto Z.A., Clarke V.R.J., Delany C.M., Parry M.C., Smolders I., Vignes M., Ho K.H., Miu P., Brinton B.T., Fantaske R., Ogden A., Gates M., Ornstein P.L., Lodge D., Bleakman D., and Collingridge G.L. Kainate receptors are involved in synaptic plasticity. Nature 402 (1999) 297-301
7. Brorson J.R., Li D., and Suzuki T. Selective expression of heteromeric AMPA receptors driven by flip-flop differences. J. Neurosci. 24 (2004) 3461-3470
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
9. Christensen J.K., Paternain A.V., Selak S., Ahring P.K., and Lerma J. A mosaic of functional kainate receptors in hippocampal interneurons. J. Neurosci. 24 (2004) 8986-8993
10. Członkowska A., Siemiatkowski M., and Plaznik A. Some behavioral effects of AMPA/kainate receptor agonists and antagonists. J. Physiol. Pharmacol. 48 (1997) 479-488
11. Dominguez E., Iyengar S., Shannon H.E., Bleakman D., Alt A., Arnold B.M., Bell M.G., Bleisch T.J., Buckmaster J.L., Castano A.M., Del Prado M., Escribano A., Filla S.A., Ho K.H., Hudziak K.J., Jones C.K., Martinez-Perez J.A., Mateo A., Mathes B.M., Mattiuz E.L., Ogden A.M., Simmons R.M., Stack D.R., Stratford R.E., Winter M.A., Wu Z., and Ornstein P.L. Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. J. Med. Chem. 48 (2005) 4200-4203
12. Ko S., Zhao M.-G., Toyoda H., Qiu C.-S., and Zhuo M. Altered behavioral responses to noxious stimuli and fear in glutamate receptor 5 (GluR5)- or GluR6-deficient mice. J. Neurosci. 25 (2005) 977-984
13. Kotlinska J., and Liljequist S. The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol. Biochem. Behav. 60 (1998) 119-124
14. Li H., Chen A., Xing G., Wei M.-L., and Rogawski M.A. Kainate receptor-mediated heterosynaptic facilitation in the amygdala. Nat. Neurosci. 4 (2001) 612-620
15. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., and Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40 (2001) 1028-1033
16. Mansour M., Nagarajan N., Nehring R.B., Clements J.D., and Rosenmund C. Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron 32 (2001) 841-853
17. Martínez G., Ropero C., Funes A., Flores E., Blotta C., Landa A.I., and Gargiulo P.A. Effects of selective NMDA and non-NMDA blockade in the nucleus accumbens on the plus-maze test. Physiol. Behav. 76 (2002) 219-224
18. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
19. Millan M.J., and Brocco M. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur. J. Pharmacol. 463 (2003) 67-96
20. Palecek J., Neugebauer V., Carlton S.M., Iyengar S., and Willis W.D. The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates. Pain 111 (2004) 151-161
21. Ploghaus A., Narain C., Beckmanhn C.F., Clare S., Bantick S., Wise R., Matthews P.M., Rawlins J.N.P., and Tracey I. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J. Neurosci. 21 (2001) 9896-9903
22. Rorick-Kehn L.M., Hart J.C., and McKinzie D.L. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl.) 183 2 (2005 Dec) 226-240
23. Sang C.N., Hostetter M.P., Gracely R.H., Chappell A.S., Schoepp D.D., Lee G., Whitcup S., Caruso R., and Max M.B. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 89 (1998) 1060-1067
24. Sheftell F.D., and Atlas S.J. Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache 42 (2002) 934-944
25. Simmons R.M.A., Li D.L., Ho K.H., Deverill M., Ornstein P.L., and Iyengar S. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 37 (1998) 25-36
26. Spooren W., and Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics?. Drug News Perspect. 17 (2004) 251-257
27. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2005) 131-144
28. Swedberg M.D., Jocobsen P., and Honore T. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). J. Pharmacol. Exp. Ther. 274 (1995) 1113-1121
29. Vandergriff J., Huff K., Bond A., and Lodge D. Binding of an AMPA receptor potentiator ([3H]LY395153) to native and recombinant AMPA receptors. Neuropharmacology 40 (2001) 1010-1018